Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jeegar P. Patel
Observed names:
Jeegar P Patel,
Jeegar Patel
Institution:
Kadmon Corporation (United States)
Observed institutions:
Kadmon Corporation (United States),
Drexel University
OpenAlex ID:
A5111630062
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease
2021
·
Madan Jagasia
, Aleksandr Lazaryan
, et al.
·
Journal of Clinical Oncology
·
198
Inhibition of glucose transport synergizes with chemical or genetic disruption of mitochondrial metabolism and suppresses TCA cycle-deficient tumors
2021
·
Kellen Olszewski
, Anthony Barsotti
, et al.
·
Cell chemical biology
·
75
PDF
Modulation of neuronal CXCR4 by the μ-opioid agonist DAMGO
2006
·
Jeegar P Patel
, Rajarshi Sengupta
, et al.
·
Journal of NeuroVirology
·
61
Apoptotic and Antiapoptotic Effects of CXCR4: Is It a Matter of Intrinsic Efficacy? Implications for HIV Neuropathogenesis
2004
·
Muhammad Z. Khan
, Renato Brandimarti
, et al.
·
AIDS Research and Human Retroviruses
·
55
Regulation of neuronal P53 activity by CXCR4
2005
·
Muhammad Z. Khan
, Saori Shimizu
, et al.
·
Molecular and Cellular Neuroscience
·
48
Human immunodeficiency virus gp120-induced apoptosis of human neuroblastoma cells in the absence of CXCR4 internalization
2006
·
Giuseppe Bardi
, Rajarshi Sengupta
, et al.
·
Journal of NeuroVirology
·
45
Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses
2020
·
Stella A. Martomo
, Dan Lu
, et al.
·
Molecular Cancer Therapeutics
·
33
Discovery and Optimization of Glucose Uptake Inhibitors
2020
·
Kevin G. Liu
, Ji-In Kim
, et al.
·
Journal of Medicinal Chemistry
·
29
A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors
2022
·
Olivier Schueller
, Ashley Willson
, et al.
·
Clinical Pharmacology in Drug Development
·
17
Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]‐Belumosudil in Healthy Men: A Phase 1, Open‐Label, 2‐Part Study
2022
·
Olivier Schueller
, Ed Skucas
, et al.
·
Clinical Pharmacology in Drug Development
·
12
Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects
2022
·
Olivier Schueller
, John McDermott
, et al.
·
Clinical Pharmacology in Drug Development
·
10
Abstract 2590: KD019: Blood brain barrier penetrant HER2/neu, Src, and EGFR inhibitor
2015
·
James R. Tonra
, Masha Poyurovsky
, et al.
·
Cancer Research
·
8
Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo
2022
·
Stella A. Martomo
, Jeegar Patel
·
Cancer Immunology Immunotherapy
·
7
PDF
Two‐Part Phase 1 Study to Evaluate the Taste Profile of Novel Belumosudil Oral Suspensions and Assess the Relative Bioavailability and Food Effect of the Selected Belumosudil Oral Suspension Compared With Oral Tablet Reference in Healthy Male Participants
2024
·
Olivier Schueller
, Galit Regev
, et al.
·
Clinical Pharmacology in Drug Development
·
6
PDF
Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.
2021
·
Jason J. Luke
, Anthony J. Olszanski
, et al.
·
Journal of Clinical Oncology
·
6
A Phase 1 Thorough QT/QTc Study of Therapeutic and Supratherapeutic Doses of Belumosudil in Healthy Subjects
2022
·
Olivier Schueller
, Lauren Lohmer
, et al.
·
Clinical Pharmacology in Drug Development
·
5
Functional antibody characterization via direct structural analysis and information‐driven protein–protein docking
2021
·
Rafael S. Depetris
, Dan Lu
, et al.
·
Proteins Structure Function and Bioinformatics
·
5
PDF
PD-1–targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer
2026
·
Isaraphorn Pratumchai
, Marie Bernardo
, et al.
·
JCI Insight
·
2
PDF
In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor
2025
·
Olivier Schueller
, Lauren Lohmer
, et al.
·
The Journal of Clinical Pharmacology
·
2
Abstract CT227: A phase 1 multiple ascending dose study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of KD033 in subjects with metastatic or locally advanced solid tumors
2021
·
Jason J. Luke
, Anthony J. Olszanski
, et al.
·
Cancer Research
·
2
Pharmacological profile and therapeutic evaluation of ROC-101, a potent and selective ROCK inhibitor, in arterial hypertension and pulmonary fibrosis
2025
·
Rigen Mo
, Sarah Lucas
, et al.
·
Pharmacological Research
·
1
114 EVO301: an IL18BP-SAFA biologic demonstrates prolonged residence in inflamed skin and efficacy in a preclinical atopic dermatitis model
2025
·
Jamie Harden
, Robert Whitener
, et al.
·
Journal of Investigative Dermatology
·
1
PDF
Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment
2025
·
Olivier Schueller
, Virginie Esposito
, et al.
·
Clinical and Translational Science
·
1
PDF
Transcriptional profiling of primary human-skin derived mast cell activation by various MRGPRX2 agonists and inhibition with EVO756
2024
·
Sreya Bagchi
, Jeegar Patel
, et al.
·
The Journal of Immunology
·
1
Abstract 2972: Preclinical characterization of SAR445877, an anti-PD-1 antibody-IL-15 mutein fusion protein with robust anti-tumor efficacy as monotherapy and in combination with PD-L1 blockade
2023
·
Marie Bernardo
, Yu-an Zhang
, et al.
·
Cancer Research
·
1
Show more works
View as search
Works count:
50
Citation count:
635
H-index:
10
I10-index:
11
Year
Topic
Type
